NewLink Genetics ($NLNK), the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market. Merck ($MRK), which has all of those skills, has signed on with a licensing agreement to research, develop, manufacture and distribute NewLink's vaccine, which is still in Phase I trials. Merck is expected to manufacture the vaccine with its Vero technology, which relies on cells from African green monkeys. Merck uses Vero to make its RotaTeq children's vaccine. Report